bucladesine has been researched along with mitomycin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ishii, K; Kusano, S; Matama, S; Matsuki, S; Shibata, H; Sugimoto, M | 1 |
| Fukui, H; Kitagami, K; Matsumoto, M; Nakano, H; Nakayama, M; Okamoto, Y; Tsujii, T | 1 |
| Smyth, MJ | 1 |
| Aoyama, T; Kimura, H; Otsu, Y | 1 |
| Ishii, K; Karube, H; Okabe, H; Okudaira, M; Shibata, H; Tsuchiya, M | 1 |
| Hasegawa, T; Koshiura, R; Matsunaga, T; Miyamoto, K; Satake, T; Takagi, K | 1 |
| Azuma, M; Hayashi, Y; Oishi, Y; Sato, M; Yanagawa, T; Yoshida, H; Yura, Y | 1 |
| Felten, S; Gash, DM; Gupta, M; Notter, MF | 1 |
| Koshiura, R; Matsunaga, T; Miyamoto, K; Waki, Y | 1 |
| Rocklin, RE | 1 |
| Iwasaki, M; Koshiura, R; Miyamoto, K; Sanae, F | 1 |
| Aoyama, T; Kimura, H; Otsu, Y; Shinohara, S; Yamada, T | 1 |
| Iwasaki, M; Koshiura, R; Matsunaga, T; Miyamoto, K | 1 |
| Sugimoto, M | 1 |
| Basson, MD; Sgambati, SA; Zarif, A | 1 |
| Endo, T; Ishii, K; Kaji, T; Katayama, M; Kosuda, S; Kusano, S; Sugimoto, M; Uematsu, M | 1 |
| Ekmekcioglu, C; Marktl, W; Strauss-Blasche, G | 1 |
18 other study(ies) available for bucladesine and mitomycin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Is necrosis induction therapy relevant to hepatocellular carcinoma? Prognostic evaluation viewed from necrosing feature in HCC occluding the main portal vein after treatment with DBcAMP and MMC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bucladesine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin; Necrosis; Portal Vein; Prognosis; Radiography; Survival Analysis | 1992 |
[Effect of dibutyryl cyclic AMP in the treatment of hepatocellular carcinoma--intraarterial infusion therapy combined with anticancer agent for hepatocellular carcinoma with portal vein thrombosis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bucladesine; Carcinoma, Hepatocellular; Doxorubicin; Female; Humans; Infusion Pumps; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Portal Vein; Thrombosis | 1992 |
Mechanisms of cytotoxicity used by human peripheral blood T-cell subsets.
Topics: Bucladesine; CD4 Antigens; CD8 Antigens; Cholera Toxin; Cycloheximide; Cyclosporine; Cytotoxicity, Immunologic; Dactinomycin; Egtazic Acid; Emetine; Humans; Lymphocyte Activation; Mitomycin; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha | 1992 |
Methylisobutylxanthine, a potent inhibitor of cAMP phosphodiesterase, enhances the sensitivity of Chinese hamster ovary cells to mitomycin C.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Bucladesine; Cell Survival; Cells, Cultured; Cricetinae; Dose-Response Relationship, Drug; Interphase; Mitomycin; Mitomycins; Theophylline | 1987 |
Arterial infusion of combination therapy using dibutyryl adenosine 3',5'-monophosphate and mitomycin C for hepatocellular carcinoma occluding main portal vein: case studies.
Topics: Adult; Aged; Bucladesine; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Portal Vein | 1989 |
Comparative studies on the combined cytotoxic effect of forskolin with mitomycin C and responsiveness to forskolin in rat ascites hepatoma AH66 cells and AH66F cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bucladesine; Cell Line; Cell Survival; Colforsin; Liver Neoplasms, Experimental; Mitomycin; Mitomycins; Rats | 1987 |
Enhancement of cis-diamminedichloroplatinum and mitomycin C-induced sister chromatid exchanges by dibutyryl cyclic AMP in a human salivary gland adenocarcinoma cell line in culture.
Topics: Adenocarcinoma; Bucladesine; Cisplatin; Drug Synergism; Humans; Mitomycin; Mitomycins; Salivary Gland Neoplasms; Sister Chromatid Exchange; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1988 |
Differentiation characteristics of human neuroblastoma cells in the presence of growth modulators and antimitotic drugs.
Topics: Acetylcholinesterase; Bromodeoxyuridine; Bucladesine; Cell Line; Cells, Cultured; Dopamine; Humans; Microscopy, Electron; Microscopy, Electron, Scanning; Mitomycin; Mitomycins; Neuroblastoma; Norepinephrine; Organoids; Prostaglandins E; Serotonin | 1985 |
Enhancement of mitomycin C uptake by isoproterenol in rat ascites hepatoma.
Topics: Animals; Ascites; Bucladesine; Cell Line; Cell Survival; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Drug Synergism; Female; Isoproterenol; Liver Neoplasms, Experimental; Mitomycin; Mitomycins; Rats | 1986 |
Physicochemical characterization and pharmacologic modulation of the synthesis and/or secretion of histamine-induced suppressor factor (HSF).
Topics: Antimetabolites; Bucladesine; Histamine; Humans; In Vitro Techniques; Leukocytes; Lymphokines; Mitomycin; Mitomycins; Suppressor Factors, Immunologic; T-Lymphocytes, Regulatory | 1983 |
Effect of beta-adrenergic stimulants on cytotoxicity of mitomycin C in HeLa cells.
Topics: Adrenergic beta-Agonists; Bucladesine; Cell Survival; Colony-Forming Units Assay; Drug Synergism; HeLa Cells; Humans; Isoproterenol; Mitomycin; Mitomycins | 1982 |
Modification of the sensitivity of CHO cells to mitomycin C by dibutyryl cyclic AMP.
Topics: Animals; Bucladesine; Cell Line; Cell Survival; Cricetinae; Cricetulus; Female; Mitomycin; Mitomycins; Ovary | 1983 |
Relationship between enhancement of cytotoxic effect of mitomycin C and increase of intracellular cyclic adenosine 3':5'-monophosphate by isoproterenol in rat ascites hepatoma cells.
Topics: Animals; Bucladesine; Cell Survival; Cells, Cultured; Cyclic AMP; Female; Isoproterenol; Liver Neoplasms, Experimental; Mitomycin; Mitomycins; Propranolol; Rats; Time Factors | 1983 |
[Arterial infusion of combination therapy using dibutyryl adenosine 3',5'-monophosphate and mitomycin C for nodular type of hepatocellular carcinoma non-occluding the main portal vein--in comparison with transcatheter arterial embolization].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bucladesine; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Portal Vein; Survival Rate | 1994 |
Octreotide differentially modulates human Caco-2 intestinal epithelial cell proliferation and differentiation by decreasing intracellular cAMP.
Topics: Alkaline Phosphatase; Antibiotics, Antineoplastic; Antigens, CD; Bucladesine; Caco-2 Cells; Cell Adhesion; Cell Adhesion Molecules; Cell Count; Cell Differentiation; Cell Division; Cell Movement; Collagen; Cyclic AMP; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Epidermal Growth Factor; Gastrointestinal Agents; Humans; Integrin alpha1; Integrins; Intestinal Mucosa; Laminin; Microvilli; Mitomycin; Octreotide | 1996 |
Intraarterial infusion of dibutyryl cyclic adenosine monophosphate plus mitomycin C for unresectable hepatocellular carcinoma: long-term survival and response to tumor growth inhibition.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bucladesine; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Mitomycin; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed | 1995 |
The plasma membrane Fe(3+)-reductase activity of Caco-2 cells is modulated during differentiation.
Topics: Alkaline Phosphatase; Bucladesine; Caco-2 Cells; Cell Differentiation; Cell Division; Colforsin; Culture Media, Serum-Free; Ferric Compounds; Ferricyanides; FMN Reductase; Humans; Insulin; Microvilli; Mitomycin; NAD; NADH, NADPH Oxidoreductases; Nitrilotriacetic Acid; Oxidation-Reduction; Phenylephrine; Sucrase; Triiodothyronine | 1998 |